Seeking Alpha 13 April 15
Obviously, the Celgene announcement was very good news for Mesoblast, and there are three obvious reasons for the share price increase.
Firstly, it provides a US vehicle (if Celgene takes up the first right of refusal on the project) for its most advanced program, JR-031 for treating acute GVHD (filed for approval in Japan).
Secondly, a group of other Mesoblast programs are included in the first right of refusal, so this is a potential opportunity to fast track other programs.
Thirdly, on the corporate front, Celgene's interest might put some pressure on TEVA (NYSE:TEVA), which has close to a 20% stake in Mesoblast through its acquisition of Cephalon. TEVA also has a major partnership with Mesoblast on chronic heart disease, with phase 3 trials in progress.
For full report see
http://seekingalpha.com/article/306...559813c8533d86478967cc5e7642d50&uprof=45&dr=1
(20min delay)